Nyxoah SA (NYXH)

Market Cap	239.27M
Revenue (ttm)	4.68M
Net Income (ttm)	-61.33M
Shares Out	37.43M
EPS (ttm)	-1.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,325
Open	6.24
Previous Close	6.32
Day's Range	6.03 - 6.38
52-Week Range	5.55 - 12.21
Beta	0.65
Analysts	Strong Buy
Price Target	14.50 (+133.87%)
Earnings Date	May 16, 2025

About NYXH

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 2, 2021
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: NYXH
• Website: https://www.nyxoah.com

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 4 analysts, the average rating for NYXH stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 133.87% from the latest price.

Price Target

$14.5

(133.87% upside)

Analyst Consensus: Strong Buy